Pinealon
ProtocolFor protocol designers building Pinealon into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 5-10 mg 1x daily for 10-20 day cycles dose at Short plasma; durable tissue effects half-life informs which scheduling pattern fits.
Key Takeaways
Scheduling lens: Pinealon's Short plasma; durable tissue effects half-life via subq/intranasal places it in the daily-dosing bucket. Mechanism: Penetrates cells, enters the nucleus, and modulates gene expression. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Protocol calendar planning for Pinealon is shaped by mechanism, pharmacokinetics, and operational reality. Penetrates cells, enters the nucleus, and modulates gene expression. Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators. The subsections below work through the daily timing patterns, the 8-12 week cycle structure with calibrated off-period, the stack scheduling principles, and the travel-and-disruption playbook.
Cycle length and off-cycle planning
Standard Pinealon cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Pinealon protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Pinealon schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Daily and weekly timing
Pinealon with a Short plasma; durable tissue effects half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily for 10-20 day cycles, with consistency mattering more than the absolute clock time of any single dose.
The most-asked scheduling question for Pinealon in tapered cycles is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
Schedule design for Pinealon in periodised cycles starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
For maintenance phase scheduling, Pinealon is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
The most-asked scheduling question for Pinealon in off-time is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 5-10 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 3-10 mg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 5-10 mg | 1x daily for 10-20 day cycles |
| Maintenance phase | SubQ | 4-10 mg | Ongoing with periodic pauses |
Dose timing for Pinealon is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Pinealon stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- Pinealon + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Pinealon's mechanism in protocol / scheduling / cycling protocols.
- Pinealon + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Pinealon's mechanism in protocol / scheduling / cycling protocols.
- Pinealon + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Pinealon's mechanism in protocol / scheduling / cycling protocols.
- Pinealon + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Pinealon's mechanism in protocol / scheduling / cycling protocols.
Excellent. Decades of safety data in Russian research.
Lens-specific safety considerations for protocol / scheduling / cycling use of Pinealon: Excellent. Decades of safety data in Russian research. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Can I shift my schedule with travel?
Cycle length and off-cycle period?
Daily timing for Pinealon?
When to integrate Pinealon into an existing stack?
What is the standard dosing protocol for Pinealon?
What does Pinealon stack well with?
Start a Pinealon Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified Pinealon and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 418 Da
- Sequence length
- 3 aa
- Half-life
- Short plasma; durable tissue effects
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Russian clinical trials; limited Western data
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Pinealon unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for Pinealon
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised